ストックスクリーナーアプリを入手
10.79
3.95%
0.4096
前日終値:
$10.38
開ける：
$10.3
24時間の取引高:
799.29K
Relative Volume:
0.51
時価総額：
$788.39M
収益：
当期純損益:
$-148.00M
株価収益率:
-2.4356
EPS:
-4.4299
ネットキャッシュフロー:
$-135.66M
1週間 パフォーマンス:
+0.65%
1か月 パフォーマンス:
-17.76%
6か月 パフォーマンス:
+96.17%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$10.13
$10.87
1週間の範囲:
$9.97
$12.73
52週間の値動き範囲:
$3.76
$15.15
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
10.79 | 788.39M | 0 | -148.00M | -135.66M | -4.4299 |
VRTX
Vertex Pharmaceuticals Inc
|
509.10 | 129.04B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.23 | 95.11B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.96 | 82.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
847.89 | 53.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.80 | 42.06B | 5.76B | 514.49M | 1.10B | 4.4813 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-27 | 開始されました | Wells Fargo | Overweight |
| 2026-04-13 | 開始されました | TD Cowen | Buy |
| 2026-02-02 | 開始されました | Jefferies | Buy |
| 2025-03-13 | 開始されました | Guggenheim | Buy |
| 2021-11-19 | ダウングレード | Maxim Group | Buy → Hold |
Helus Pharma Inc (HELP) 最新ニュース
Helus Pharma Inc. (CN:HELP) Rallies 10.53% as Positive Momentum Sharpens Investor Focus - kalkine.ca
What Is Riding on Helus Pharma's Phase Three Readout? - Kalkine Media
Helus Pharma remains a buy ahead of key Phase 3 data for HLP003 expected in late 2026. - Pluang
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout (NASDAQ:HELP) - Seeking Alpha
Helus Pharma (DB:R7E0)Rendimiento de beneficios e ingresos - Simply Wall Street
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Connect Biopharma Holdings (CNTB) and Helus Pharma (HELP) - The Globe and Mail
Cybin D/B/A Helus Pharma (HELP) Options Chain - Yahoo! Finance Canada
Helus Pharma (NEOE:HELP)Análisis de acciones - Simply Wall Street
Cybin D/B/A Helus Pharma (HELP) stock price, news, quote and history - Yahoo Finance Singapore
Helus Pharma (HELP) will discuss depression and anxiety drugs at its investor webcast - Stock Titan
H.C. Wainwright reiterates Helus Pharma stock rating at buy - Investing.com
Helus Pharma to present updates on depression a... - Pluang
Helus Pharma to Host Investor Presentation on October 21, 2026 Highlighting HLP003 and HLP004 Development Programs - Quiver Quantitative
Helus Pharma to Host Investor Presentation on October 21, 2026Thu, 10/08/202607:30 - Helus Pharma
Helus Pharma Stock Under Pressure: Clinical Risk and Bearish Momentum Raise Correction Concerns - kalkine.ca
Helus Pharma Stock Drops 7.29% as Volatility Builds Ahead of Pivotal Phase 3 APPROACH Readout for HLP003 (CN:HELP) - kalkine.ca
Form 6-K Helus Pharma Inc. For: Oct 01 - StreetInsider
[6-K] CYBIN INC. Current Report (Foreign Issuer) - Stock Titan
Helus Pharma Stock Faces Renewed Pressure as Bearish Momentum Raises Correction Risk — Healthcare - kalkine.ca
Helus Pharma (NasdaqGM:HELP) Stock Forecast & Analyst Predictions - Simply Wall Street
HELPInterventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption - Simply Wall Street
Helus Pharma Inc.: Target Price Consensus and Analysts Recommendations | CLXPF | CA4234921076 - marketscreener.com
Helus Pharma Inc.: Financial Data Forecasts Estimates and Expectations | CLXPF | CA4234921076 - marketscreener.com
Helus Pharma (NasdaqGM:HELP)Rendimiento de beneficios e ingresos - Simply Wall Street
Helus Pharma Inc. (HELP) análisis del equipo directivo y de gestión - Simply Wall Street
No shareholder action is needed as Cybin (HELP) becomes Helus Pharma and keeps its ticker. - Stock Titan
Form 4 Helus Pharma Inc. For: 1 October By Investing.com - Investing.com Canada
Form 4 Helus Pharma Inc. For: 1 October By Investing.com - Investing.com Nigeria
Helus Pharma Finalizes Legal Name Change as It Prepares for Commercial Push - TipRanks
Helus Pharma (HELP) Officially Changes Legal Name from Cybin Inc. on October 1, 2026 - GuruFocus
Cybin rebrands to Helus Pharma, ticker symbol unchanged - Investing.com
CapEx per share of Helus Pharma Inc. – HAN:R7E - TradingView
Helus Pharma Announces Completion of Legal Name ChangeThu, 10/01/202607:30 - Helus Pharma
Helus Pharma Announces Completion of Legal Name Change - Yahoo Finance
Cybin Changes Legal Name to Helus Pharma - Yahoo Finance
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression - Yahoo Finance
Nearly 99% of Cybin (HELP) investors vote for a new name - Stock Titan
Helus Pharma Announces Annual and Special Meeting Voting Results and Legal Name Change to Helus Pharma Inc. - quiverquant.com
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board - Yahoo Finance
Cybin Inc. Common Stock (NASDAQ: HELP) Share Price, HELP Stock News, HELP Share Price & Updates - kalkine.ca
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026Mon, 09/21/202607:30 - Helus Pharma
Cybin (CN:HELP) Falls 5.91% as Clinical-Stage Risk and Phase 3 Expectations Pressure Sentiment - kalkine.ca
Helus Pharma at Cantor conference: phase III readout in focus - investing.com
Helus Pharma at Cantor conference: phase III readout in focus - Investing.com India
Cybin Executive Chair Eric H. L. So Acquires 100,000 Shares in Voluntary Filing - Kalkine Media
CYBIN INC. (NASDAQ: HELP) Executive Eric So Holds Sole Authority Over 4.37 Million Shares - Kalkine Media
Phase 3 depression drug in focus as Cybin's Helus Pharma (HELP) joins Morgan Stanley event - Stock Titan
Cybin (NASDAQ:HELP) Shares Down 5.5%Here's Why - MarketBeat
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New YorkThu, 09/10/202607:30 - Helus Pharma
Executive chair buys 95,000 Cybin (HELP) shares in latest stake filing - Stock Titan
Helus Pharma Inc (HELP) 財務データ
収益
当期純利益
現金流量
EPS
Helus Pharma Inc (HELP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Halstead Michael | Chief Executive Officer |
Sep 21 '26 |
Buy |
13.47 |
100,000 |
1,347,050 |
168,568 |
| Glavine Paul | Chief Growth Officer |
Sep 08 '26 |
Buy |
12.47 |
100,000 |
1,247,190 |
4,271,252 |
| So Eric H. L. | Executive Chair |
Sep 08 '26 |
Buy |
12.39 |
100,000 |
1,238,670 |
4,465,014 |
| Glavine Paul | Chief Growth Officer |
Sep 08 '26 |
Buy |
12.47 |
100,000 |
1,247,190 |
4,271,252 |
| So Eric H. L. | Executive Chair |
Sep 04 '26 |
Buy |
12.09 |
100,000 |
1,208,900 |
4,365,014 |
| Glavine Paul | Chief Growth Officer |
Sep 03 '26 |
Buy |
11.78 |
100,000 |
1,178,280 |
4,171,252 |
| So Eric H. L. | Executive Chair |
Sep 01 '26 |
Buy |
11.80 |
95,000 |
1,121,475 |
4,265,014 |
| Glavine Paul | Chief Growth Officer |
Aug 31 '26 |
Buy |
11.59 |
90,000 |
1,042,677 |
4,071,252 |
2.52%
0.87%
大文字化:
|
ボリューム (24 時間):